Christopher R. Heery
YOU?
Author Swipe
View article: Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Constructing the cure: engineering the next wave of antibody and cellular immune therapies Open
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in hematologic malignancies and select soli…
View article: The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor
The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor Open
Background Chordomas are rare tumors arising from the skull base and spine, with approximately 20 pediatric chordoma cases in the Unitedn States per year. The natural history and optimal treatment of pediatric chordomas, especially poorly …
View article: Avelumab in Patients With Metastatic Colorectal Cancer
Avelumab in Patients With Metastatic Colorectal Cancer Open
Background Metastatic colorectal cancer (mCRC) is incurable, and median overall survival is less than 2½ years. Although monoclonal antibodies that block PD-1/PD-L1 interactions are active in microsatellite unstable/mismatch repair deficie…
View article: Supplementary Figure 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 90K, Consort diagram.
View article: Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells Open
Dose response curves for avelumab-mediated ADCC assays of 3 human cancer cell lines using purified NK cells from the same healthy donor as effectors at an effector:target ratio of 25:1.
View article: Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells Open
Dose response curves for avelumab-mediated ADCC assays of 3 human cancer cell lines using purified NK cells from the same healthy donor as effectors at an effector:target ratio of 25:1.
View article: Data from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Data from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PSA-TRICOM (PROSTVAC) is a novel vector-based vaccine designed to generate a robust immune response against prostate-specific antigen (PSA)-expressing tumor cells. The purpose of this report is to present an overview of both published stud…
View article: Supplementary Tables 1 - 2 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Supplementary Tables 1 - 2 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells Open
Supplementary Table S1. Pre-treating PBMC with IL-2 did not affect ADCC induced by avelumab of the human lung carcinoma cell line H441. Supplementary Table S2. Pre-treating purified NK cells with IL-12 did not increase ADCC activity mediat…
View article: Data from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Data from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy Open
Tumor immunoscore analyses, especially for primary colorectal cancer and melanoma lesions, provide valuable prognostic information. Metastatic lesions of many carcinoma types, however, are often not easily accessible. We hypothesized that …
View article: Supplemental Table 1 from A Blueprint to Advance Colorectal Cancer Immunotherapies
Supplemental Table 1 from A Blueprint to Advance Colorectal Cancer Immunotherapies Open
S1. Therapeutic strategies and corresponding laboratory tests.
View article: Supplementary Materials and Methods from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Supplementary Materials and Methods from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy Open
Custom software for the calculation of the peripheral immunoscore.
View article: Supplementary Figure 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 62K, IL-5 following vaccine.
View article: Supplementary Figures 1 through 3 and Supplementary Tables 1 through 3 from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Supplementary Figures 1 through 3 and Supplementary Tables 1 through 3 from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy Open
Supplementary Figure S1: Gating strategy to identify classic peripheral immune cell types and refined immune cell subsets with phenotypes reflecting immune function that were used to generate the peripheral immunoscores of patients treated…
View article: Supplementary Table 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Table 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
XLSX file - 32K, Adverse events.
View article: Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies
Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies Open
Supplemental Tables 1 and 2
View article: Supplementary Table 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Table 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 43K, Antigen cascade.
View article: Supplementary Table 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Table 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
XLSX file - 32K, Adverse events.
View article: Supplementary Figure 3 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 3 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 264K, Tumor growth rates following vaccine.
View article: Supplementary Figure 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 1 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 90K, Consort diagram.
View article: Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies
Supplemental Table Legends from A Blueprint to Advance Colorectal Cancer Immunotherapies Open
Supplemental Tables 1 and 2
View article: Supplemental Figure 1 from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Supplemental Figure 1 from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury Open
Yeast-brachyury progression-free survival; chordoma patients only.
View article: Supplementary Figure 3 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 3 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 264K, Tumor growth rates following vaccine.
View article: Supplementary Figure 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Supplementary Figure 2 from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PDF file - 62K, IL-5 following vaccine.
View article: Data from A Blueprint to Advance Colorectal Cancer Immunotherapies
Data from A Blueprint to Advance Colorectal Cancer Immunotherapies Open
Immunotherapy is rapidly becoming a standard of care for many cancers. However, colorectal cancer had been generally resistant to immunotherapy, despite features in common with sensitive tumors. Observations of substantial clinical activit…
View article: Supplemental Figure 1 from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Supplemental Figure 1 from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury Open
Yeast-brachyury progression-free survival; chordoma patients only.
View article: Data from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Data from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer Open
PSA-TRICOM (PROSTVAC) is a novel vector-based vaccine designed to generate a robust immune response against prostate-specific antigen (PSA)-expressing tumor cells. The purpose of this report is to present an overview of both published stud…
View article: Data from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Data from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells Open
Several anti–PD-1/PD-L1 monoclonal antibodies (mAb) are currently providing evidence of clinical benefit in subsets of cancer patients. The mode of action of these mAbs is to inhibit PD-1 on immune cells interacting with PD-L1 on tumor cel…
View article: Data from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Data from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy Open
Tumor immunoscore analyses, especially for primary colorectal cancer and melanoma lesions, provide valuable prognostic information. Metastatic lesions of many carcinoma types, however, are often not easily accessible. We hypothesized that …
View article: Data from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Data from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury Open
The nuclear transcription factor brachyury has previously been shown to be a strong mediator of the epithelial-to-mesenchymal transition (EMT) in human carcinoma cells and a strong negative prognostic factor in several tumor types. Brachyu…
View article: Data from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Data from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury Open
The nuclear transcription factor brachyury has previously been shown to be a strong mediator of the epithelial-to-mesenchymal transition (EMT) in human carcinoma cells and a strong negative prognostic factor in several tumor types. Brachyu…